TEST BANK FOR CLAYTON’S BASIC PHARMACOLOGY FOR NURSES 18TH EDITION

TEST BANK FOR CLAYTON’S BASIC PHARMACOLOGY FO
w w w w w w



R NURSES 19th EDITION BY MICHELLE WILLIHNGANZ CH
w w w w w w w



APTER 1-48 w




Chapter 01: Drug Definitions, Standards, and Information Sources Willihnganz: Clayton’s Ba
w w w w w w w w w w


sic Pharmacology for Nurses, 19th Edition
w w w w w




MULTIPLEwCHOICE

1. WhichwnamewidentifieswawdrugwlistedwbywthewUSwFoodwand
DrugwAdministrationw(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS:w C
Thewofficialwnamewiswthe
namewunderwwhichwawdrugwiswlisted
wbywthewFDA.wThewbrandwname,worwtrademark, wiswthewnamewg

ivenwtowawdrugwbywitswmanufacturer.wThewnonproprietary,worw
generic,wnamew isw providedw bywthew Unitedw Statesw Adopted
wNameswCouncil.

DIF:wCognitivewLevel:wKnowledge REF:wp.w9
OBJ:w1NAT:wNCLEXwClientwNeedswCategory:wSafe,wEffectivewCarewEnvironme
ntwTOP:wNursingwProcesswStep:wAssessment CON:
PatientwEducation

2. Whichwsourcewcontainswinformationwspecificwtownutritionalwsupplements?
a. USPwDictionarywofwUSANw&wInternationalwDrugwNames
b. NaturalwMedicineswComprehensivewDatabase
c. UnitedwStateswPharmacopoeia/NationalwFormularyw(USPwNF)
d. DrugwInteractionwFacts
ANS:wC
UnitedwStateswPharmacopoeia/NationalwFormularywcontainswinformationwspecificwtow nutrition
alwsupplements.wUSPwDictionarywofwUSANw&wInternationalwDrugwNameswiswawcompilationwofw
drugwnames,wpronunciationwguide,wandwpossiblewfuturewFDAwapprovedwdrugs;witwdoeswnotwincl
udewnutritionalwsupplements.wNaturalwMedicineswComprehensivewDatabasewcontainswevidence
-
basedwinformationwonwherbalwmedicineswandwherbalwcombinationwproducts;witwdoeswnotwinclude
winformationwspecificwtownutritionalwsupplements. wDrugwInteraction wFacts wcontainswcomprehen

sivewinformationwonwdrugwinteractionwfacts;witwdoeswnotwincludewnutritionalwsupplements.

DIF:wCognitivewLevel:wKnowledge REF:wp.w4
OBJ:w3wNAT:wNCLEXwClie
ntwNeedswCategory:wPhysiologicalwIntegrity
TOP:wNursingwProcesswStep:wAssessment CON:wNutritionw|wPatientwEducation

,TestwBankwForwClayton’swBasicwPharmacologywforwNursesw19thwEditio 2
n 3. Whichwdrugwreferencewcontainswdrugwmonographswthatwdescribewallwdrugswinwawtherapeuticwclass?
a. DrugwFactswandwComparisons
b. DrugwInteractionwFacts
c. HandbookwonwInjectablewDrugs
d. Martindale—ThewCompletewDrugwReference
ANS:wA
DrugwFactswandwComparisonswcontainswdrugwmonographswthatwdescribewallwdrugswinw
awtherapeuticwclass.wMonographswarewformattedwaswtableswtowallowwcomparisonwofwsim
ilarwproducts,wbrandwnames,wmanufacturers,wcostwindices,wandwavailablewdosagewform
swOnlinewversionwiswavailable.

DIF:wCognitivewLevel:wKnowledge REF:wp.w4wTablew1.2
OBJ:w w 3 NAT:wNCLEXwClientwNeedswCategory:wPhysiologicalwIntegrity
TOP:wNursingwProcesswStep:wAssessment CON:wSafetyw|wPatientwEducationw|wClinicalwJudgment

4. Whichwdrugwreferencewcontainswmonographswaboutwvirtuallyweverywsingle-
entitywdrugwavailablewinwthewUnitedwStateswandwdescribeswtherapeuticwuseswofwdrugs,wincludin
gwapprovedwandwunapprovedwuses?
a. Martindale:wThewCompletewDrugwReference
b. AHFSwDrugwInformation
c. DrugwReference
d. DrugwFactswandwComparisons
ANS:wB
AHFSwDrugwInformationwcontainswmonographswaboutwvirtuallyweverywsingle-
entitywdrugwavailablewinwthewUnitedwStateswandwdescribeswtherapeuticwuseswofwdrugs,wincludingw
approvedwandwunapprovedwuses.

DIF:wCognitivewLevel:wKnowledge REF:wp.w4wTablew1.2
OBJ:w w 3 NAT:wNCLEXwClientwNeedswCategory:wPhysiologicalwIntegrity
TOP:wNursingwProcesswStep:wPlanning CON:wSafetyw|wPatientwEducationw|wClinicalwJudgment

5. Whichw onlinew drugw referencew makesw availablew tow healthcarew providersw andw thew publicw
awstandard,wcomprehensive,wup-to-
datewlookwupwandwdownloadablewresourcewaboutwmedicines?
a. AmericanwDrugwIndex
b. AmericanwHospitalwFormulary
c. DailyMed
d. DrugwReference
ANS:wC
DailyMedwmakeswavailablewtowhealthcarewproviderswandwthewpublicwawstandard,wcomprehensiv
e,wup-to-
datewlookwupwandwdownloadablewresourcewaboutwmedicines.wThewAmericanwDrugwIndexwiswnotw
appropriatewforwpatientwuse.wThewAmericanwHospitalwFormularywiswnotwappropriatewforwpatien
twuse.wThewdrugwreferencewiswnotwappropriatewforwpatientwuse.

DIF:wCognitivewLevel:wKnowledge REF:wp.w3w|wp.w4
OBJ:w3wNAT:wNCLEXwClie
ntwNeedswCategory:wPhysiologicalwIntegrity
TOP:wNursingwProcesswStep:wImplementation
CON:wSafetyw|wPatientwEducationw|wClinicalwJudgment

6. WhichwlegislationwauthorizeswthewFDAwtowdeterminewthewsafetywofwawdrugwbeforewitswmarketing?
a. FederalwFood,wDrug,wandwCosmeticwActw(1938)

,TestwBankwForwClayton’swBasicwPharmacologywforwNursesw19thwEditio 3
n b. DurhamwHumphreywAmendmentw(1952)
c. ControlledwSubstanceswActw(1970)
d. KefauverwHarriswDrugwAmendmentw(1962)
ANS:wA
ThewFederalwFood,wDrug,wandwCosmeticwActwofw1938wauthorizedwthewFDAwtowdeterminewthews
afetywofwallwdrugswbeforewmarketing.wLaterwamendmentswandwactswhelpedwtightenwFDAwcontrol
wandwensurewdrugwsafety.wThewDurhamwHumphreywAmendmentwdefines wthewkindswofwdrugs wtha

twcannotwbewusedwsafelywwithoutwmedicalwsupervisionwandwrestrictswtheirwsalewtowprescriptionwb
ywawlicensedwpractitioner.wThewControlledwSubstanceswActwaddresseswonlywcontrolledwsubstanc
eswandwtheirwcategorization.wThewKefauverwHarriswDrugwAmendmentwensureswdrugwefficacywa
ndwgreaterwdrugwsafety.wDrugwmanufacturerswarewrequiredwtowprovewtowthewFDAwtheweffectivene
sswofwtheirwproductswbeforewmarketingwthem.

DIF:wCognitivewLevel:wKnowledge REF:w p.w5wTablewl.3
OBJ:w5
NAT:wNCLEXwClientwNeedswCategory:wPhysiologicalwIntegrit
ywTOP:wNursingwProcesswStep:wAssessment
CON:wSafetyw|wPatientwEducationw|wEvidencew|wHealthwCarewLaw

7. Whichwclassificationwdoeswmeperidinew(Demerol)wfallwunder?wa.
I
b. II
c. III
d. IV
ANS:wB
Meperidinew(Demerol)wiswawSchedulewIIwdrug;witwhaswawhighwpotentialwforwabusewandwmaywleadw
towseverewpsychologicalwandwphysicalwdependence.wSchedulewIwdrugswhavewhighwpotentialwforw
abusewandwnowrecognizedwmedicalwuse.wSchedulewIIIwdrugswhavewsomewpotentialwforwabuse.wUs
ewmaywleadwtowlowwtowmoderatewphysicalwdependenceworwhighwpsychologicalwdependence.
SchedulewIVwdrugswhavewlowwpotentialwforwabuse.wUsewmaywleadwtowlimitedwphysicalworwpsych
ologicalwdependence.

DIF:wCognitivewLevel:wKnowledge REF:wp.w10
OBJ:w2wNAT:wNCLEXwClie
ntwNeedswCategory:wSafe,wEffectivewCarewEnvironment
TOP:wNursingwProcesswStep:wAssessment CON:wPatientwEducationw|wAddictionw|wPain

8. WhichwactionwwouldwthewFDAwtakewtowexpeditewdrugwdevelopmentwandwapprovalwforwanwoutbrea
kwofwsmallpox?
a. Listwsmallpoxwaswawhealthworphanwdisease.
b. Omitwthewpreclinicalwresearchwphase.
c. Extendwthewclinicalwresearchwphase.
d. Fastwtrackwthewinvestigationalwdrug.
ANS:wD
OncewthewInvestigationalwNewwDrugwApplicationwhaswbeenwapproved,wthewdrugwcanwreceivewhi
ghestwprioritywwithinwthewagency,wwhichwiswcalledwfastwtracking.wAwsmallpoxwoutbreakwwouldw
becomewawprioritywconcernwinwthewworld.wOrphanwdiseaseswarewnotwresearchedwinwawprioritywma
nner.wPreclinicalwresearchwiswnotwomitted.wExtendingwanywphasewofwthewresearchwwouldwmeanwa
wlongerwtimewtowdevelop wawvaccine.wThewFDAwmustwensurewthatwallwphaseswofwthewpreclinicalwa

ndwclinicalwresearchwphasewhavewbeenwcompletedwinwawsafewmanner.

DIF:wCognitivewLevel:wKnowledge REF:wp.w7 OBJ:w5

, TestwBankwForwClayton’swBasicwPharmacologywforwNursesw19thwEditio 4
n NAT:wNCLEXwClientwNeedswCategory:wSafe,wEffectivewCarewEnvironmen
twTOP:wNursingwProcesswStep:wAssessment
CON:wHealthwCarewLaww|wHealthwCarewPolicyw|wInfectionw|wCarewCoordination

9. Whichwstatementwiswtruewaboutwover-the-counterw(OTC)wdrugs?
a. TheywarewnotwlistedwinwthewUSPwNF.
b. Awprescriptionwfromwawhealthcarewproviderwiswneeded.
c. Theywarewsoldwwithoutwawprescription.
d. Theywarewknownwonlywbywtheirwbrandwnames.
ANS:wC
OTCwmedicationswdownotwrequirewawprescription.wAwvarietywofwnames,wbothwgenericwandwtrade,
wcanwbewusedwforwindividualwdrugs wsoldwOTC.wOTC wdrugswarewlistedwinwthewUSPwNF.wPrescripti

onwdrugswrequirewanworderwbywawhealthwprofessionalwwhowiswlicensedwtowprescribe,wsuchwaswawp
hysician,wnursewpractitioner,wphysicianwassistant,worwdentist.

DIF:wCognitivewLevel:wComprehension REF:wp.w2
OBJ:w2wNAT:wNCLEXwClie
ntwNeedswCategory:wPhysiologicalwIntegrity
TOP:wNursingwProcesswStep:wPlanning CON:wPatientwEducation

10. Whichwiswthewmostwauthoritativewreferencewforwmedicationswthatwarewinjected?
a. Martindale:wThewComplete
b. HandbookwonwInjectablewDrugs
c. DailyMed
d. HandbookwofwNonprescriptionwDrugs
ANS:wB
ThewHandbookwonwInjectablewDrugswiswthewmostwcomprehensivewreferencewavailablewonwthewt
opicwofwcompatibilitywofwinjectablewdrugs.wItwiswawcollectionwofwmonographswforwmorewthanw30
0winjectablewdrugswthatwarewlistedwalphabeticallywbywgenericwname.

DIF:wCognitivewLevel:wKnowledge REF:wp.w4
OBJ:w3wNAT:wNCLEXwClie
ntwNeedswCategory:wPhysiologicalwIntegrity
TOP:wNursingwProcesswStep:wAssessment CON:wClinicalwJudgmentw|wSafety

11. WhichwstatementwiswtruewaboutwLomotil?
a. Abusewpotentialwforwthiswdrugwiswlow.
b. Psychologicalwdependencywiswlikely.
c. Therewiswawhighwpotentialwforwabuse.
d. Thiswdrugwiswnotwawcontrolledwsubstance.
ANS:wA
Lomotil,wawSchedulewVwdrug,whaswanwabusewpotentialwofwlimitedwphysicalworwpsychologicalwde
pendencewliabilitywcomparedwwithwdrugswinwSchedulewIV.wBecausewabusewpotentialwiswlowwwit
hwawSchedulewVwdrug,wawprescriptionwmaywnotwbewrequired.wPsychologicalwdependencywiswnotwl
ikelywwithwawSchedulewVwdrug.wSchedulewVwdrugswarewclassifiedwaswcontrolledwsubstances.

DIF:wCognitivewLevel:wKnowledge REF:wp.w5wBoxw1.1
OBJ:w2wNAT:wNCLEXwClie
ntwNeedswCategory:wPhysiologicalwIntegrity
TOP:wNursingwProcesswStep:wAssessment CON:wClinicalwJudgmentw|wSafetyw|wPatientwEducation
12. Whichwmedicationworderedwforwawpatientwwithwawsubstancewabusewhistorywhaswthewgreate
stwriskwforwabuse?
a. Lomotil